APA (7th ed.) Citation

Kimmich, C., Terzer, T., Benner, A., Hansen, T., Carpinteiro, A., Dittrich, T., . . . Hegenbart, U. (2021). Daratumumab, lenalidomide, and dexamethasone in systemic light-chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21. American journal of hematology, 96(7), . https://doi.org/10.1002/ajh.26191

Chicago Style (17th ed.) Citation

Kimmich, Christoph, et al. "Daratumumab, Lenalidomide, and Dexamethasone in Systemic Light-chain Amyloidosis: High Efficacy, Relevant Toxicity and Main Adverse Effect of Gain 1q21." American Journal of Hematology 96, no. 7 (2021). https://doi.org/10.1002/ajh.26191.

MLA (9th ed.) Citation

Kimmich, Christoph, et al. "Daratumumab, Lenalidomide, and Dexamethasone in Systemic Light-chain Amyloidosis: High Efficacy, Relevant Toxicity and Main Adverse Effect of Gain 1q21." American Journal of Hematology, vol. 96, no. 7, 2021, https://doi.org/10.1002/ajh.26191.